Amgen 2011 Annual Report Download - page 152
Download and view the complete annual report
Please find page 152 of the 2011 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.-
1 -
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11
-
12
-
13
-
14
-
15
-
16
-
17
-
18
-
19
-
20
-
21
-
22
-
23
-
24
-
25
-
26
-
27
-
28
-
29
-
30
-
31
-
32
-
33
-
34
-
35
-
36
-
37
-
38
-
39
-
40
-
41
-
42
-
43
-
44
-
45
-
46
-
47
-
48
-
49
-
50
-
51
-
52
-
53
-
54
-
55
-
56
-
57
-
58
-
59
-
60
-
61
-
62
-
63
-
64
-
65
-
66
-
67
-
68
-
69
-
70
-
71
-
72
-
73
-
74
-
75
-
76
-
77
-
78
-
79
-
80
-
81
-
82
-
83
-
84
-
85
-
86
-
87
-
88
-
89
-
90
-
91
-
92
-
93
-
94
-
95
-
96
-
97
-
98
-
99
-
100
-
101
-
102
-
103
-
104
-
105
-
106
-
107
-
108
-
109
-
110
-
111
-
112
-
113
-
114
-
115
-
116
-
117
-
118
-
119
-
120
-
121
-
122
-
123
-
124
-
125
-
126
-
127
-
128
-
129
-
130
-
131
-
132
-
133
-
134
-
135
-
136
-
137
-
138
-
139
-
140
-
141
-
142 -
143 -
144 -
145 -
146 -
147 -
148 -
149 -
150 -
151 -
152 -
153 -
154 -
155 -
156 -
157 -
158 -
159 -
160 -
161 -
162 -
163
-
164
-
165
-
166
-
167
-
168
-
169
-
170
-
171
-
172
-
173
-
174
-
175
-
176
-
177
-
178
-
179
-
180
-
181
-
182
-
183
-
184
 |
 |
AMGEN INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
12. Intangible assets
Finite-lived and indefinite-lived identifiable intangible assets consisted of the following as of December 31,
2011 and 2010 (in millions):
2011 2010
Gross
carrying
amount
Accumulated
amortization
Intangible
assets, net
Gross
carrying
amount
Accumulated
amortization
Intangible
assets, net
Finite-lived intangible assets:
Acquired product technology rights:
Developed product technology ......... $2,872 $(1,811) $1,061 $2,872 $(1,619) $1,253
Core technology .................... 1,348 (850) 498 1,348 (760) 588
Trade name ........................ 190 (120) 70 190 (107) 83
Acquired R&D technology rights ........ 350 (350) — 350 (329) 21
Other acquired intangible assets .......... 686 (406) 280 627 (342) 285
Total finite-lived intangible assets .... 5,446 (3,537) 1,909 5,387 (3,157) 2,230
Indefinite-lived intangible
assets — IPR&D ..................... 675 — 675 — — —
Total identifiable intangible assets .......... $6,121 $(3,537) $2,584 $5,387 $(3,157) $2,230
Amortization of finite-lived intangible assets is provided over their estimated useful lives ranging from 5 to
15 years on a straight-line basis.
Acquired product technology rights relate to the identifiable intangible assets acquired in connection with
the 2002 Immunex acquisition and the related amortization expense is included in Amortization of certain
acquired intangible assets in the Consolidated Statements of Income. Acquired R&D technology rights consist of
technology used in R&D with alternative future uses and the related amortization expense is included in
Research and development expense in the Consolidated Statements of Income. The amortization expense related
to other acquired intangible assets is included principally in Cost of sales (excludes amortization of certain
acquired intangible assets) and Selling, general and administrative expense in the Consolidated Statements of
Income. During the years ended December 31, 2011, 2010 and 2009, we recognized amortization charges
associated with our finite-lived intangible assets of $380 million, $423 million and $425 million, respectively.
The total estimated amortization for each of the next five years for our intangible assets is $354 million, $359
million, $340 million, $327 million and $317 million in 2012, 2013, 2014, 2015 and 2016, respectively.
IPR&D relates to identifiable intangible assets acquired in connection with the acquisition of BioVex. (See
Note 2, Business combinations — BioVex Group, Inc.)
F-28